Related content

INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies

By  

Current Bioactive Compounds, Vol. 7, Iss. 1, 2011-03 ,pp. : 33-38

Bentham Science Publishers

Access to resources Recommend Favorite

Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?

By Pectasides Dimitris   Psyrri Amanda   Pectasides Melina   Economopoulos Theofanis  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. : 975-987

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of the tumor targeting of a FAPαα-based doxorubicin prodrug

By Huang Sichao   Fang Rui   Xu Jun   Qiu Shenghong   Zhang Huan   Du Jun   Cai Shaohui  

Journal of Drug Targeting, Vol. 19, Iss. 7, 2011-08 ,pp. : 487-496

Informa Healthcare

Access to resources Recommend Favorite

HPLC-MS/MS determination of a peptide conjugate prodrug of doxorubicin, and its active metabolites, leucine-doxorubicin and doxorubicin, in dog and rat plasma

By Mazuel C.   Grove J.   Gerin G.   Keenan K.P.  

Journal of Pharmaceutical and Biomedical Analysis, Vol. 33, Iss. 5, 2003-12 ,pp. : 1093-1102

Elsevier

Access to resources Recommend Favorite

A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy

By Ibsen Stuart   Zahavy Eran   Wrasdilo Wolf   Berns Michael   Chan Michael   Esener Sadik  

Pharmaceutical Research, Vol. 27, Iss. 9, 2010-09 ,pp. : 1848-1860

Springer Publishing Company

Access to resources Recommend Favorite